a
a
Weather:
No weather information available
HomeHealthAnti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial

Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial

Nature Medicine, Published online: 03 June 2025; doi:10.1038/s41591-025-03739-y

A single dose of the anti-sporozoite monoclonal antibody CIS43LS can achieve durable, sterile protection against Plasmodium falciparum infection.

No comments

Sorry, the comment form is closed at this time.

Translate »